Corrigendum to “Efficacy + safety of palbociclib (P) in patients (pts) ≤50 y with hormone receptor‒positive (HR+)/human epidermal growth factor receptor 2‒negative (HER2–) advanced breast cancer (ABC): Subgroup analysis of 2 randomized phase 3 studies” (The Breast (2018) 41(S1) (S11–S12), (S0960977618301760), (10.1016/j.breast.2018.08.033))

Massimo Cristofanilli; Nadia Harbeck; Hope S. Rugo; Aurelio Castrellon; Anil Abraham Joy; Sunil Verma; Seock Ah Im; Shrividya Iyer; Kathy Puyana Theall; Eric Gauthier; Xin Huang; Cynthia Huang Bartlett; Sibylle Loibl; Richard S. Finn

doi:10.1016/j.breast.2019.11.010

Corrigendum to “Efficacy + safety of palbociclib (P) in patients (pts) ≤50 y with hormone receptor‒positive (HR+)/human epidermal growth factor receptor 2‒negative (HER2–) advanced breast cancer (ABC): Subgroup analysis of 2 randomized phase 3 studies” (The Breast (2018) 41(S1) (S11–S12), (S0960977618301760), (10.1016/j.breast.2018.08.033))

Massimo Cristofanilli, Nadia Harbeck, Hope S. Rugo, Aurelio Castrellon, Anil Abraham Joy, Sunil Verma, Seock Ah Im, Shrividya Iyer, Kathy Puyana Theall, Eric Gauthier, Xin Huang, Cynthia Huang Bartlett, Sibylle Loibl, Richard S. Finn

Research output: Contribution to journal › Comment/debate

Abstract

Two of the authors’ names appeared incorrectly in the byline. The correct names are Anil Abraham Joy and Kathy Puyana Theall.

Original language	English
Pages (from-to)	131
Number of pages	1
Journal	Breast
Volume	49
DOIs	https://doi.org/10.1016/j.breast.2019.11.010
State	Published - Feb 2020

Bibliographical note

Publisher Copyright:
© 2019 Elsevier Ltd

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.breast.2019.11.010

Fingerprint

Dive into the research topics of 'Corrigendum to “Efficacy + safety of palbociclib (P) in patients (pts) ≤50 y with hormone receptor‒positive (HR+)/human epidermal growth factor receptor 2‒negative (HER2–) advanced breast cancer (ABC): Subgroup analysis of 2 randomized phase 3 studies” (The Breast (2018) 41(S1) (S11–S12), (S0960977618301760), (10.1016/j.breast.2018.08.033))'. Together they form a unique fingerprint.

Cite this

Cristofanilli, M., Harbeck, N., Rugo, H. S., Castrellon, A., Joy, A. A., Verma, S., Im, S. A., Iyer, S., Puyana Theall, K., Gauthier, E., Huang, X., Bartlett, C. H., Loibl, S., & Finn, R. S. (2020). Corrigendum to “Efficacy + safety of palbociclib (P) in patients (pts) ≤50 y with hormone receptor‒positive (HR+)/human epidermal growth factor receptor 2‒negative (HER2–) advanced breast cancer (ABC): Subgroup analysis of 2 randomized phase 3 studies” (The Breast (2018) 41(S1) (S11–S12), (S0960977618301760), (10.1016/j.breast.2018.08.033)). Breast, 49, 131. https://doi.org/10.1016/j.breast.2019.11.010

Cristofanilli, Massimo ; Harbeck, Nadia ; Rugo, Hope S. et al. / Corrigendum to “Efficacy + safety of palbociclib (P) in patients (pts) ≤50 y with hormone receptor‒positive (HR+)/human epidermal growth factor receptor 2‒negative (HER2–) advanced breast cancer (ABC) : Subgroup analysis of 2 randomized phase 3 studies” (The Breast (2018) 41(S1) (S11–S12), (S0960977618301760), (10.1016/j.breast.2018.08.033)). In: Breast. 2020 ; Vol. 49. pp. 131.

@article{0e465afde8a54212acd4679317ab16fb,

title = "Corrigendum to “Efficacy + safety of palbociclib (P) in patients (pts) ≤50 y with hormone receptor‒positive (HR+)/human epidermal growth factor receptor 2‒negative (HER2–) advanced breast cancer (ABC): Subgroup analysis of 2 randomized phase 3 studies” (The Breast (2018) 41(S1) (S11–S12), (S0960977618301760), (10.1016/j.breast.2018.08.033))",

abstract = "Two of the authors{\textquoteright} names appeared incorrectly in the byline. The correct names are Anil Abraham Joy and Kathy Puyana Theall.",

author = "Massimo Cristofanilli and Nadia Harbeck and Rugo, {Hope S.} and Aurelio Castrellon and Joy, {Anil Abraham} and Sunil Verma and Im, {Seock Ah} and Shrividya Iyer and {Puyana Theall}, Kathy and Eric Gauthier and Xin Huang and Bartlett, {Cynthia Huang} and Sibylle Loibl and Finn, {Richard S.}",

note = "Publisher Copyright: {\textcopyright} 2019 Elsevier Ltd",

year = "2020",

month = feb,

doi = "10.1016/j.breast.2019.11.010",

language = "English",

volume = "49",

pages = "131",

journal = "Breast",

issn = "0960-9776",

publisher = "Churchill Livingstone",

}

Cristofanilli, M, Harbeck, N, Rugo, HS, Castrellon, A, Joy, AA, Verma, S, Im, SA, Iyer, S, Puyana Theall, K, Gauthier, E, Huang, X, Bartlett, CH, Loibl, S & Finn, RS 2020, 'Corrigendum to “Efficacy + safety of palbociclib (P) in patients (pts) ≤50 y with hormone receptor‒positive (HR+)/human epidermal growth factor receptor 2‒negative (HER2–) advanced breast cancer (ABC): Subgroup analysis of 2 randomized phase 3 studies” (The Breast (2018) 41(S1) (S11–S12), (S0960977618301760), (10.1016/j.breast.2018.08.033))', Breast, vol. 49, pp. 131. https://doi.org/10.1016/j.breast.2019.11.010

Corrigendum to “Efficacy + safety of palbociclib (P) in patients (pts) ≤50 y with hormone receptor‒positive (HR+)/human epidermal growth factor receptor 2‒negative (HER2–) advanced breast cancer (ABC): Subgroup analysis of 2 randomized phase 3 studies” (The Breast (2018) 41(S1) (S11–S12), (S0960977618301760), (10.1016/j.breast.2018.08.033)). / Cristofanilli, Massimo; Harbeck, Nadia; Rugo, Hope S. et al.
In: Breast, Vol. 49, 02.2020, p. 131.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Corrigendum to “Efficacy + safety of palbociclib (P) in patients (pts) ≤50 y with hormone receptor‒positive (HR+)/human epidermal growth factor receptor 2‒negative (HER2–) advanced breast cancer (ABC)

T2 - Subgroup analysis of 2 randomized phase 3 studies” (The Breast (2018) 41(S1) (S11–S12), (S0960977618301760), (10.1016/j.breast.2018.08.033))

AU - Cristofanilli, Massimo

AU - Harbeck, Nadia

AU - Rugo, Hope S.

AU - Castrellon, Aurelio

AU - Joy, Anil Abraham

AU - Verma, Sunil

AU - Im, Seock Ah

AU - Iyer, Shrividya

AU - Puyana Theall, Kathy

AU - Gauthier, Eric

AU - Huang, Xin

AU - Bartlett, Cynthia Huang

AU - Loibl, Sibylle

AU - Finn, Richard S.

PY - 2020/2

Y1 - 2020/2

N2 - Two of the authors’ names appeared incorrectly in the byline. The correct names are Anil Abraham Joy and Kathy Puyana Theall.

AB - Two of the authors’ names appeared incorrectly in the byline. The correct names are Anil Abraham Joy and Kathy Puyana Theall.

UR - http://www.scopus.com/inward/record.url?scp=85075628192&partnerID=8YFLogxK

U2 - 10.1016/j.breast.2019.11.010

DO - 10.1016/j.breast.2019.11.010

M3 - Comment/debate

AN - SCOPUS:85075628192

SN - 0960-9776

VL - 49

SP - 131

JO - Breast

JF - Breast

ER -

Cristofanilli M, Harbeck N, Rugo HS, Castrellon A, Joy AA, Verma S et al. Corrigendum to “Efficacy + safety of palbociclib (P) in patients (pts) ≤50 y with hormone receptor‒positive (HR+)/human epidermal growth factor receptor 2‒negative (HER2–) advanced breast cancer (ABC): Subgroup analysis of 2 randomized phase 3 studies” (The Breast (2018) 41(S1) (S11–S12), (S0960977618301760), (10.1016/j.breast.2018.08.033)). Breast. 2020 Feb;49:131. doi: 10.1016/j.breast.2019.11.010